Clinical Trial Detail

NCT ID NCT04148937
Title A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Eli Lilly and Company
Indications

lung cancer

breast cancer

ovarian cancer

prostate cancer

kidney cancer

melanoma

pancreatic cancer

Therapies

LY3475070

LY3475070 + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.